Hodgkin's Lymphoma | Lymphoid Leukemia | Non-Hodgkin's Lymphoma
Managed Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release
Volunteers
Health Professionals
What is the purpose of this trial?
Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Alfredo Axtmayer
- Amer Zeidan, MBBS
- Amy Pugliese
- Carolyn Demsky, APRN
- Francine Foss, MD
- Iris Isufi, MD
- Kerri Ann Rall
- Lisa Barbarotta
- Lisa Rivera
- Lohith Gowda, MD, MRCP
- Manoj M Pillai, MBBS
- Maureen McGlennon
- Meifeng Shen
- Michael Hurwitz, MD, PhD
- Niketa C Shah, MD
- Noffar Bar, MD
- Stephanie Kacik
- Stuart Seropian, MD
- Thomas Prebet, MD, PhD
- Last Updated11/22/2024
- Study HIC#2000025634